PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)

PHASE3CompletedINTERVENTIONAL
Enrollment

3,659

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Critical IllnessDeep Venous Thrombosis
Interventions
DRUG

LMWH (Fragmin, dalteparin)

Placebo AM dose (normal saline) and LMWH (Fragmin, dalteparin) 5000IU PM dose

DRUG

Unfractionated Heparin

5000 IU BID

Trial Locations (67)

2148

Blacktown Hospital, Blacktown

3101

Royal Melbourne Hospital, Melbourne

3168

Dandenong Hospital, Dandenong

3181

The Alfred Hospital, Melbourne

3220

The Geelong Hospital, Geelong

5112

Lyell McEwin Hospital, Elizabeth Vale

11426

King Abdulaziz Medical City Hospital, Riyadh

21418

King Abdulaziz University Hospital, Jeddah

55905

Mayo Clinic, Rochester

63141

St. John's Mercy Medical Center, St Louis

77030

MD Anderson, Houston

02903

Rhode Island Hospital, Providence

Unknown

Royal Prince Alfred Hospital, Camperdown

Nepean Hospital, Penrith

Wollongong Hospital, Wollongong

Royal Adelaide Hospital, Adelaide

Flinders Hospital, Bedford Park

Bendigo Health Care, Bendigo

Box Hill Hospital, Box Hill

Monash Medical Center, Clayton

Frankston Hospital, Frankston

Austin Hill Hospital, Heidelburg

UTI da Enfermaria de Clinical Medica do Hospital, São Paulo

Hospital ProCardiaco, Rio de Janeiro

Hospital Coracao, São Paulo

University of Alberta, Edmonton

Surry Memorial, Surrey

Vancouver Island Health Authority, Victoria

Guelph General Hospital, Guelph

Hamilton Health Science Center - Henderson Hospital, Hamilton

London Health Science Center, London

Lakeridge Health, Oshawa

Toronto General Hospital, Toronto

Hopital Maisonneuve, Montreal

King Faisal Specialist & Research Center, Jeddah

King Fahad Medical City, Riyadh

Riyadh Military Hospital, Riyadh

Guys and St Thomas Hospital, London

NSW 2065

Royal North Shore Hospital, St Leonards

90020-200

Hospitalar Santa Casa, Porto Alegre

90035-001

Hospital Moinhos de Vento, Porto Alegre

T2N 2T9

Foothills Hospital, Calgary

TiY 6J4

The Peter Lougheed Hospital, Calgary

T5H 3V9

Royal Alexandra Hospital, Edmonton

V3L 3W4

Royal Columbian Hospital, Vancouver

V5Z 1M9

Vancouver General Hospital, Vancouver

V6Z 1Y6

St Paul's Hospital, Vancouver

R2H 2A6

St. Boniface Hospital, Winnipeg

B3H 3A7

Queen Elizabeth II Health, Halifax

L8N 3Z5

Hamilton Health Science Centre - Hamilton General Hospital, Hamilton

Hamilton Health Science Centre - McMaster University, Hamilton

L8N 4A6

St Joseph's HealthCare, Hamilton

K7L 2V7

Kingston General Hospital, Kingston

N2G 1G3

Grand River Hospital, Kitchener

K1H 8L6

Ottawa Hospital - General Hospital, Ottawa

K1Y 4E9

Ottawa Hospital - Civic Site, Ottawa

M4N 3M5

Sunnybrook and Women's College Health Science Centre, Toronto

M5B 1W8

St Michaels Hospital, Toronto

M5G 1X5

Mount Sinai Hospital, Toronto

M5T 2S8

University Health Network - Toronto Western Hospital, Toronto

H3A 1A1

Royal Victoria Hospital, McGill University Health Center, Montreal

H3G 1A4

Montreal General Hospital, McGill University Health Centre, Montreal

H4J 2C5

Hopital Sacre Couer, Montreal

J4V 2H1

Hopital Charles LeMoyne, Montreal

G1J 1Z4

Centre Hospitalier Affilie-Enfant Jesus, Québec

G1V 4G5

Hopital Laval, Québec

J1H 5N4

Sherbrooke University (CHUS) Hospital, Sherbrooke

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Canadian Critical Care Trials Group

OTHER

collaborator

Australian and New Zealand Intensive Care Society Clinical Trials Group

NETWORK

lead

McMaster University

OTHER

NCT00182143 - PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) | Biotech Hunter | Biotech Hunter